This announcement is a separate document:
国金证券股份有限公司关于江苏南方卫材医药股份有限公司重大资产购买之2021年度持续督导意见暨持续督导总结报告
Guojin Securities Co., Ltd. 2021 continuous Supervision opinion and Summary report on Major Asset purchase of Jiangsu Southern Eisai Pharmaceutical Co., Ltd.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.